Super-Enhancer–FOXA1–SLC7A11 Axis Drives Disulfidptosis in Prostate Cancer

Study Background and Research Question

Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men worldwide, with advanced cases often progressing to a castration-resistant state that resists standard androgen deprivation therapy. Recent years have seen increasing interest in non-apoptotic cell death pathways, such as ferroptosis and necroptosis, for their roles in tumor suppression and therapy resistance. Disulfidptosis, a distinct form of programmed cell death characterized by cytoskeletal collapse in the context of glucose deprivation and elevated cystine metabolism, has emerged as a potential target for therapeutic intervention. However, the regulatory mechanisms upstream of disulfidptosis in PCa have not been fully elucidated (Kang et al., 2025).

Key Innovation from the Reference Study

The article by Kang et al. identifies a previously uncharacterized regulatory axis linking super-enhancer (SE) activity to the expression of SLC7A11 via the transcription factor FOXA1. This SE/FOXA1/SLC7A11 axis orchestrates susceptibility to disulfidptosis under glucose-limiting conditions in prostate cancer cells. The authors further demonstrate that pharmacological or genetic disruption of this pathway can protect cells from disulfidptosis, highlighting a new potential intervention point for advanced PCa (Kang et al., 2025).

Methods and Experimental Design Insights

Kang et al. employed a multi-tiered approach combining bioinformatics, gene editing, and functional assays:

• Integrated analyses of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets to identify disulfidptosis-related genes in PCa.
• Generation of SLC7A11-overexpressing and knockout cell lines to study the functional impact on proliferation, migration, invasion, and cell death modalities.
• Induction of disulfidptosis through glucose starvation and the glucose uptake inhibitor BAY-876.
• Chromatin profiling using CUT&Tag and ChIP-seq to map FOXA1 binding and super-enhancer regions.
• Luciferase reporter assays to confirm transcriptional regulation of SLC7A11 by FOXA1.
• CRISPR-Cas9-mediated deletion of the identified super-enhancer (chr14:37583488–37589585) to assess downstream effects on FOXA1 and SLC7A11 expression and cell fate.

This integrated workflow enabled the authors to dissect both the upstream chromatin regulatory events and the downstream functional consequences, including application of apoptosis and cell cycle arrest assays to characterize the cell death phenotype.

Protocol Parameters

• apoptosis assay | annexin V/PI staining, flow cytometry | detection of disulfidptosis-induced cell death | differentiates between apoptosis, necrosis, and disulfidptosis | paper
• cell cycle arrest assay | PI staining, flow cytometry | assessment of G1/S/G2M phase distribution | monitors impact of SLC7A11 modulation on proliferation | paper
• SLC7A11 overexpression | lentiviral transduction, MOI 10–20 | functional studies in PCa lines | enables causality tests for gene function | paper
• glucose deprivation | 0 mM glucose for 24–48 h | triggers disulfidptosis in SLC7A11-high cells | models tumor microenvironmental stress | paper
• BAY-876 treatment | 1–10 µM for 24–48 h | pharmacologic induction of glucose deprivation | validates metabolic triggers | paper
• CRISPR-Cas9 SE deletion | paired sgRNAs, 1–5 µg | functional validation of enhancer dependency | defines regulatory causality | paper
• I-BET151 (GSK1210151A) application | 0.25–1 µM (workflow_recommendation) | BET bromodomain inhibition in enhancer studies | disrupts BRD4-mediated chromatin regulation | workflow_recommendation

Core Findings and Why They Matter

The central findings of Kang et al. are as follows:

• SLC7A11 promotes proliferation, migration, and invasion in PCa cells. Overexpression renders cells susceptible to disulfidptosis under glucose-deprived conditions.
• Disulfidptosis can be induced pharmacologically using BAY-876, confirming the role of metabolic stress in this cell death pathway.
• FOXA1, a lineage-defining transcription factor in PCa, directly regulates SLC7A11 expression. This regulation is controlled by a super-enhancer element on chromosome 14.
• CRISPR-mediated deletion of the super-enhancer reduces FOXA1 and SLC7A11 levels, protecting cells from disulfidptosis even when glucose is limited.

These discoveries reveal a mechanistic link between chromatin architecture, transcriptional regulation, and cell death susceptibility. The work suggests that targeting super-enhancer function, or the BET family proteins that mediate enhancer-driven transcription, could be a promising strategy to sensitize PCa cells to metabolic therapies or to protect normal tissues from off-target disulfidptosis (Kang et al., 2025).

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on targeting BET bromodomains in cancer biology. For example, the article “I-BET151 (GSK1210151A): BET Inhibitor Precision in Disulfidptosis Assays” highlights how I-BET151 enables advanced, quantitative disulfidptosis and super-enhancer research in cancer models. This aligns closely with the reference study’s focus on enhancer-driven gene regulation and cell death modalities. Similarly, “I-BET151: Selective BET Inhibitor for Cancer Biology & Ep...” summarizes stepwise protocols for apoptosis and cell cycle arrest assays, both of which are central to the experimental workflow used by Kang et al. The key distinction in Kang et al.’s work is the mechanistic dissection of the SE/FOXA1/SLC7A11 axis, providing a direct link between chromatin state and metabolic cell death pathways. While internal articles emphasize technical approaches and troubleshooting for BET inhibitor experiments, the current study situates these methods within a novel biological context relevant to PCa progression and therapy resistance.

Limitations and Transferability

Despite robust multi-modal evidence, the study has several limitations:

• The majority of experiments were conducted in vitro with established cell lines; in vivo validation is required to confirm therapeutic relevance.
• Disulfidptosis, while operationally defined, may exhibit context-dependent features that differ across tumor types or microenvironmental conditions.
• The study focuses on the SE/FOXA1/SLC7A11 axis in PCa; generalization to other cancers or non-epithelial models requires further testing.

Transferability of these findings to clinical or drug development settings will depend on additional validation in patient-derived models and integration with existing therapeutic strategies, including BET bromodomain inhibitors such as I-BET151 (Kang et al., 2025).

Research Support Resources

Researchers aiming to dissect super-enhancer-mediated transcriptional regulation or to model disulfidptosis in cancer biology may find BET bromodomain inhibitors, such as I-BET151 (GSK1210151A) (SKU B1500), useful for modulating enhancer-driven gene expression in vitro. APExBIO supplies I-BET151 for preclinical research, and its application has been discussed in the context of apoptosis assay and cell cycle arrest workflows (workflow_recommendation). As always, researchers should select reagents and concentrations tailored to their specific cell model and experimental design, and refer to peer-reviewed protocols for guidance.